1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of
the Study
2.2.
Baseline
Methodology
2.3.
Key Industry
Partners
2.4.
Major
Association and Secondary Sources
2.5.
Forecasting
Methodology
2.6.
Data Triangulation
& Validation
2.7.
Assumptions
and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4. Impact of COVID-19
on Global
Transthyretin
Amyloidosis Treatment Market
5. Global Transthyretin
Amyloidosis Treatment Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1. By Type (ATTR-PN, ATTR-CM)
5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen,
Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis
(Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty
Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2024)
5.3.
Market Map
6. Asia Pacific Transthyretin
Amyloidosis Treatment Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1.
By Type
6.2.2.
By Therapy
6.2.3.
By Disease Type
6.2.4. By Distribution
Channel
6.3.
Asia Pacific: Country Analysis
6.3.1. China Transthyretin
Amyloidosis Treatment Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Type
6.3.1.2.2.
By Therapy
6.3.1.2.3.
By Disease Type
6.3.1.2.4.
By Distribution Channel
6.3.2. India Transthyretin
Amyloidosis Treatment Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Type
6.3.2.2.2.
By Therapy
6.3.2.2.3.
By Disease Type
6.3.2.2.4.
By Distribution Channel
6.3.3. Australia Transthyretin
Amyloidosis Treatment Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Type
6.3.3.2.2.
By Therapy
6.3.3.2.3.
By Disease Type
6.3.3.2.4.
By Distribution Channel
6.3.4. Japan Transthyretin
Amyloidosis Treatment Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Type
6.3.4.2.2.
By Therapy
6.3.4.2.3.
By Disease Type
6.3.4.2.4.
By Distribution Channel
6.3.5. South Korea Transthyretin
Amyloidosis Treatment Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Type
6.3.5.2.2.
By Therapy
6.3.5.2.3.
By Disease Type
6.3.5.2.4.
By Distribution Channel
7. Europe Transthyretin
Amyloidosis Treatment Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1.
By Type
7.2.2.
By Therapy
7.2.3.
By Disease Type
7.2.4. By Distribution Channel
7.2.5.
By Country
7.3.
Europe: Country Analysis
7.3.1. France Transthyretin
Amyloidosis Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
7.3.1.2.2.
By Therapy
7.3.1.2.3.
By Disease Type
7.3.1.2.4.
By Distribution Channel
7.3.2. Germany Transthyretin
Amyloidosis Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
7.3.2.2.2.
By Therapy
7.3.2.2.3.
By Disease Type
7.3.2.2.4.
By Distribution Channel
7.3.3. Spain Transthyretin
Amyloidosis Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
7.3.3.2.2.
By Therapy
7.3.3.2.3.
By Disease Type
7.3.3.2.4.
By Distribution Channel
7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
7.3.4.2.2.
By Therapy
7.3.4.2.3.
By Disease Type
7.3.4.2.4.
By Distribution Channel
7.3.5. United Kingdom Transthyretin
Amyloidosis Treatment Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
7.3.5.2.2.
By Therapy
7.3.5.2.3.
By Disease Type
7.3.5.2.4.
By Distribution Channel
8. North America Transthyretin
Amyloidosis Treatment Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Type
8.2.2. By Therapy
8.2.3. By Disease Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3.
North America: Country Analysis
8.3.1. United States Transthyretin
Amyloidosis Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
8.3.1.2.2.
By Therapy
8.3.1.2.3.
By Disease Type
8.3.1.2.4.
By Distribution Channel
8.3.2. Mexico Transthyretin
Amyloidosis Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
8.3.2.2.2.
By Therapy
8.3.2.2.3.
By Disease Type
8.3.2.2.4.
By Distribution Channel
8.3.3. Canada Transthyretin
Amyloidosis Treatment Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
8.3.3.2.2.
By Therapy
8.3.3.2.3.
By Disease Type
8.3.3.2.4.
By Distribution Channel
9. South Transthyretin
Amyloidosis Treatment Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Type
9.2.2. By Therapy
9.2.3. By Disease Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3.
South America: Country Analysis
9.3.1. Brazil Transthyretin
Amyloidosis Treatment Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Therapy
9.3.1.2.3.
By Disease Type
9.3.1.2.4.
By Distribution Channel
9.3.2. Argentina Transthyretin
Amyloidosis Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Therapy
9.3.2.2.3.
By Disease Type
9.3.2.2.4.
By Distribution Channel
9.3.3. Colombia Transthyretin
Amyloidosis Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Therapy
9.3.3.2.3.
By Disease Type
9.3.3.2.4.
By Distribution Channel
10. Middle East and
Africa Transthyretin Amyloidosis Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Type
10.2.2. By Therapy
10.2.3. By Disease Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa Transthyretin
Amyloidosis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Therapy
10.3.1.2.3.
By Disease Type
10.3.1.2.4.
By Distribution Channel
10.3.2. Saudi Arabia Transthyretin
Amyloidosis Treatment Market Outlook
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Therapy
10.3.2.2.3.
By Disease Type
10.3.2.2.4.
By Distribution Channel
10.3.3. UAE Transthyretin
Amyloidosis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Therapy
10.3.3.2.3.
By Disease Type
10.3.3.2.4.
By Distribution Channel
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global Transthyretin Amyloidosis Treatment Market: SWOT
Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business
Overview
15.1.2. Company
Snapshot
15.1.3. Products
& Services
15.1.4. Financials
(As Reported)
15.1.5. Recent
Developments
15.2. Johnson & Johnson Services Inc.
15.3. Ionis Pharmaceuticals Inc.
15.4. Alnylam Pharmaceuticals Inc.
15.5. BridgeBio Pharma Inc.
15.6. Bristol-Myers Squibb Company.
15.7. Acrotech Biopharma.
15.8. AstraZeneca Plc.
15.9 SOM Biotech.
16.
Strategic
Recommendations
17. About Us & Disclaimer